Ra Capital Management, L.P. Dyne Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $4.58 Billion
- Q2 2025
A detailed history of Ra Capital Management, L.P. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 9,714,392 shares of DYN stock, worth $220 Million. This represents 2.02% of its overall portfolio holdings.
Number of Shares
9,714,392
Previous 9,714,392
-0.0%
Holding current value
$220 Million
Previous $102 Million
8.99%
% of portfolio
2.02%
Previous 2.11%
Shares
5 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Janus Henderson Group PLC London, X09.44MShares$214 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$207 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$173 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$167 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$124 Million14.09% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.17B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...